Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
In patients with rheumatoid arthritis, a treat-to-target strategy focusing on low disease activity including through the use of low dose of prednisone, is a key determinant of bone loss prevention. Expand
Therapeutic management of hypophosphatemic rickets from infancy to adulthood
In this review, medical, dental, surgical, and contributions of various expertises to the treatment of HR are described, with an effort to highlight the importance of coordinated care. Expand
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
It is recommended that the diagnosis of XLH is based on signs of rickets and/or osteomalacia in association with hypophosphataemia and renal phosphate wasting in the absence of vitamin D or calcium deficiency. Expand
2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis.
The updated recommendations underline the need for osteoporosis pharmacotherapy in women with a history of severe osteOPorotic fracture and provide clinicians with clarifications about the pharmacological treatment of osteoporeosis. Expand
Increase in Vertebral Fracture Risk in Postmenopausal Women Using Omeprazole
Omeprazole use is associated with an increased risk of vertebral fractures in postmenopausal women and further studies are required to determine the mechanism of the association between the underlying gastric disease, omeprazoles use, and risk of osteoporotic fractures. Expand
Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids
- M. Ghazi, S. Kolta, K. Briot, J. Fechtenbaum, S. Paternotte, C. Roux
- Osteoporosis International
- 1 February 2012
Vertebral fracture assessment (VFA) is a convenient tool for the diagnosis of vertebral fracture in RA and presence of VF is inversely related to the use of DMARD and glucocorticoids, enhancing the hypothesis that an appropriate control of the disease may be a protective factor against bone fragility. Expand
Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment.
This 2-year prospective study showed a significant increase in body weight at 1 year and 2 years, mostly due to a gain in fat mass and asignificant increase in BMD, in patients with SpA receiving anti-TNF-alpha treatment. Expand
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study
- K. Briot, M. Tubiana-Hulin, L. Bastit, I. Kloos, C. Roux
- Breast Cancer Research and Treatment
- 1 February 2010
This study shows that in patients intolerant to one AI, switching to another agent allows a higher proportion of patients to continue the therapy and maximize hormonal adjuvant therapy and disease outcome benefits. Expand
Inflammatory diseases and bone fragility
- K. Briot, P. Geusens, I. Em Bultink, W. Lems, C. Roux
- Osteoporosis International
- 15 September 2017
Different clinical aspects of inflammatory diseases which illustrate the relationships between inflammation and bone fragility are presented to assess the anti-fracture efficacy of a tight control of inflammation in patients with a chronic inflammatory disorder. Expand
2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis.
- K. Briot, B. Cortet, +12 authors T. Thomas
- Joint, bone, spine : revue du rhumatisme
- 1 December 2014
This update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 is performed under the aegis of the Bone Section of the French Society for Rheumatology and Osteoporotic Research and Information Group and in collaboration with four French learned societies. Expand